PM
PMCB.US PharmaCyte Biotech Inc
- Market cap
- USD 3.09M
- P/E
- -
- P/B
- 0.14x
- ROE
- -68.2%
- Dividend yield
- 7.96%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is PMCB.US undervalued?
Graham numberThe Graham number of PharmaCyte Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PharmaCyte Biotech Inc fundamental analysis
No fundamental analysis for PharmaCyte Biotech Inc yet.
PharmaCyte Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a coo…
Full company profilePharmaCyte Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PharmaCyte Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - |
| Operating Income | -4.44M | -6.98M | -4.10M | -3.83M | -3.62M | -4.39M | -6.46M | -8.52M | -4.38M | -6.85M | -4.03M |
| EBITDA | -4.44M | -6.83M | -4.10M | -3.83M | -3.55M | -4.24M | -6.46M | -6.52M | -4.38M | -5.30M | -4.03M |
| Net Income | -4.44M | -6.83M | -4.07M | -3.83M | -3.55M | -4.24M | -4.32M | 334K | 30.7M | -19.4M | -20.3M |
| EPS | -150 | -0.01 | 0.00 | 0.00 | 0.00 | -5.19 | -4.21 | 0.66 | 79 | -44 | -36 |
| Balance Sheet | |||||||||||
| Total Assets | 8.67M | 6.41M | 5.78M | 6.17M | 7.40M | 90.6M | 73.3M | 59.9M | 55.2M | 46.8M | 36.7M |
| Total Liabilities | 580K | 644K | 743K | 1.08M | 725K | 704K | 587K | 20.4M | 3.28M | 11.8M | 6.90M |
| Shareholders' Equity | 8.09M | 5.77M | 5.04M | 5.09M | 6.68M | 89.9M | 72.7M | 39.5M | 51.9M | 33.3M | 29.8M |
| Cash & Short-term Investments | 3.46M | 1.06M | 515K | 2.47M | 2.20M | 85.4M | 68.0M | 50.2M | 15.5M | 37.1M | 30.5M |
| Total Debt | - | - | - | 75.2K | 50.8K | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.34M | -5.08M | -2.88M | -2.34M | -3.33M | -4.12M | -3.79M | -2.15M | -2.98M | -5.15M | -3.12M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 4.00 | 0.00 | 0.00 |
| Free Cash Flow | -3.34M | -5.08M | -2.88M | -2.34M | -3.33M | -4.12M | -3.79M | -2.15M | -2.98M | -5.15M | -3.12M |
| Ratios | |||||||||||
| ROE | -54.9% | -118.4% | -80.7% | -75.2% | -53.2% | -4.7% | -5.9% | 0.8% | 59.1% | -58.3% | -68.2% |
| ROA | -51.3% | -106.5% | -70.3% | -62.1% | -48.0% | -4.7% | -5.9% | 0.6% | 55.6% | -41.5% | -55.4% |
| Debt to Equity | - | - | - | 0.01x | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
PharmaCyte Biotech Inc dividends
- Dividend yield
- 7.96%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 246K | 0.56 | - |
| 2025 | USD 1.13M | 2.93 | 3.7% |
| 2024 | USD 22.5M | 45 | 6,728.5% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:19 on Nov 13, 2026.
Who owns PharmaCyte Biotech Inc
- Insiders 5.73%
- Institutions 6.32%
- Public & others 87.94%
- Shares outstanding 566K
- Free float 530K
Top funds holding PMCB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 58.2K | 0.57% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 17.5K | 0.17% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 15.3K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 12.9K | 0.13% | 0.00% | Sep 2026 |
Top institutions holding PMCB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 283K | 2.80% | -21.18% | Jun 2026 |
| Geode Capital Management, LLC | 124K | 1.23% | -36.50% | Jun 2026 |
| Renaissance Technologies Corp | 64.7K | 0.64% | +70.42% | Sep 2026 |
| Vanguard Capital Management, LLC | 56.8K | 0.56% | +10.32% | Jun 2026 |
| Susquehanna International Group, LLP | 44.9K | 0.44% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 34.2K | 0.34% | -34.72% | Jun 2026 |
| Northern Trust Corp | 32.6K | 0.32% | -8.36% | Jun 2026 |
| Jane Street Group LLC | 30.1K | 0.30% | +160.75% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 26.9K | 0.27% | -0.31% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 23.5K | 0.23% | 0.00% | Jun 2026 |
| EQUITEC PROPRIETARY MARKETS, LLC | 22.2K | 0.22% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 20.3K | 0.20% | +96.40% | Jun 2026 |
| HRT FINANCIAL LLC | 15.5K | 0.15% | -37.55% | Jun 2026 |
| Tower Research Capital LLC | 4.89K | 0.05% | -0.02% | Jun 2026 |
| UBS Group AG | 4.14K | 0.04% | -8.34% | Jun 2026 |
| Group One Trading, LLC | 500.00 | 0.00% | -71.99% | Jun 2026 |
| Advisor Group Holdings, Inc. | 303.00 | 0.00% | +0.33% | Jun 2026 |
| Covestor Ltd | 275.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 192.00 | 0.00% | 0.00% | Jun 2026 |
| Sachetta LLC | 14.00 | 0.00% | 0.00% | Jun 2026 |
PharmaCyte Biotech Inc company profile
- Company name
- PharmaCyte Biotech Inc
- Ticker
- PMCB.US
- Exchange
- USA Stocks
- Listed since
- Sep 17, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- April
- Address
- 3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169
- Phone
- 917 595 2850
- Website
- pharmacyte.com
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
PharmaCyte Biotech Inc management
4- Mr. Joshua N. SilvermanCEO. President & Executive Chairman · born 1970
- Mr. Carlos A. Trujillo CPAChief Financial Officer · born 1958
- Dr. Jose L. Iglesias M.D.Consulting Chief Medical Officer · born 1957
- Dr. Hans-Peter Hammes M.D.Member of Medical & Scientific Advisory Board and Consultant